TRIUMEQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Triumeq, and when can generic versions of Triumeq launch?
Triumeq is a drug marketed by Viiv Hlthcare and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-eight patent family members in thirty-three countries.
The generic ingredient in TRIUMEQ is abacavir sulfate; dolutegravir sodium; lamivudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.
DrugPatentWatch® Generic Entry Outlook for Triumeq
Triumeq was eligible for patent challenges on August 12, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 8, 2029. This may change due to patent challenges or generic licensing.
There have been twenty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for TRIUMEQ
International Patents: | 148 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 19 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TRIUMEQ |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TRIUMEQ |
What excipients (inactive ingredients) are in TRIUMEQ? | TRIUMEQ excipients list |
DailyMed Link: | TRIUMEQ at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for TRIUMEQ
Generic Entry Date for TRIUMEQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TRIUMEQ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
King's College London | Phase 3 |
Macquarie University, Australia | Phase 3 |
Stichting TRICALS Foundation | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for TRIUMEQ
Paragraph IV (Patent) Challenges for TRIUMEQ
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TRIUMEQ | Tablets | abacavir sulfate; dolutegravir sodium; lamivudine | 600 mg/50 mg/ 300 mg | 205551 | 5 | 2017-08-14 |
US Patents and Regulatory Information for TRIUMEQ
TRIUMEQ is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TRIUMEQ is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TRIUMEQ
Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Viiv Hlthcare | TRIUMEQ PD | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET, FOR SUSPENSION;ORAL | 215413-001 | Mar 30, 2022 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRIUMEQ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | See Plans and Pricing | See Plans and Pricing |
Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | See Plans and Pricing | See Plans and Pricing |
Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRIUMEQ
When does loss-of-exclusivity occur for TRIUMEQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 09325128
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0923217
Estimated Expiration: See Plans and Pricing
Canada
Patent: 44019
Estimated Expiration: See Plans and Pricing
Patent: 55957
Estimated Expiration: See Plans and Pricing
China
Patent: 2245182
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 76080
Estimated Expiration: See Plans and Pricing
Patent: 10603
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 43626
Estimated Expiration: See Plans and Pricing
Japan
Patent: 86478
Estimated Expiration: See Plans and Pricing
Patent: 48595
Estimated Expiration: See Plans and Pricing
Patent: 30891
Estimated Expiration: See Plans and Pricing
Patent: 12131791
Estimated Expiration: See Plans and Pricing
Patent: 12511573
Estimated Expiration: See Plans and Pricing
Patent: 16041727
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 1942
Estimated Expiration: See Plans and Pricing
Patent: 11006241
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 27451
Estimated Expiration: See Plans and Pricing
Patent: 38923
Estimated Expiration: See Plans and Pricing
Patent: 11121785
Estimated Expiration: See Plans and Pricing
Patent: 13153004
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 1308
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1733625
Estimated Expiration: See Plans and Pricing
Patent: 1847887
Estimated Expiration: See Plans and Pricing
Patent: 110094336
Estimated Expiration: See Plans and Pricing
Patent: 170038116
Estimated Expiration: See Plans and Pricing
Spain
Patent: 41765
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 83947
Estimated Expiration: See Plans and Pricing
Patent: 1030010
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TRIUMEQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Czech Republic | 284513 | (-)cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan 5-yl)-(1H)-pyrimidin-2-on v krystalické formě ((-)CIS-4-AMINO-1-(2-HYDROXYMETHYL-1,3-OXATHIOLAN-5-YL)- (1H)PYRIMIDIN-2-ONE IN CRYSTALLINE FORM, PROCESS OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF) | See Plans and Pricing |
Norway | 974510 | See Plans and Pricing | |
Australia | 1881092 | See Plans and Pricing | |
Australia | 2009325128 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | See Plans and Pricing |
European Patent Office | 0979082 | See Plans and Pricing | |
Denmark | 3045206 | See Plans and Pricing | |
China | 1185110 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TRIUMEQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0817637 | SPC016/2005 | Ireland | See Plans and Pricing | SPC016/2005: 20060407, EXPIRES: 20191216 |
0817637 | 91171 | Luxembourg | See Plans and Pricing | 91171, EXPIRES: 20191217 |
1874117 | 122014000066 | Germany | See Plans and Pricing | PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIRNATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140116 |
2465580 | CA 2021 00010 | Denmark | See Plans and Pricing | PRODUCT NAME: CABOTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1481 20201221 |
1874117 | 300676 | Netherlands | See Plans and Pricing | PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121 |
0817637 | 288 | Finland | See Plans and Pricing | |
1874117 | PA2014021 | Lithuania | See Plans and Pricing | PRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |